Tofacitinib API manufacturers are primarily located in India and China, with companies like Emcure Pharmaceuticals, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences among those producing the active pharmaceutical ingredient (API) [1][2].
Who are the main global tofacitinib API suppliers?
Major global suppliers of tofacitinib API include manufacturers based in India and China. Companies such as Emcure Pharmaceuticals, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences are key players in this market [1][2]. These manufacturers cater to both domestic and international pharmaceutical companies for the production of tofacitinib-containing finished drug products.
When does tofacitinib patent exclusivity expire?
Patent exclusivity for tofacitinib varies depending on specific patents and geographic regions. The primary patents related to tofacitinib, such as those covering its composition of matter and methods of use, have seen expiration or are nearing expiration in key markets. For instance, the Orange Book lists several patents for tofacitinib products, with various expiration dates [3]. DrugPatentWatch.com provides detailed information on patent expiration timelines for various drugs, including tofacitinib [4].
What are the risks associated with generic tofacitinib entry?
The entry of generic tofacitinib can pose several risks. For branded manufacturers, it leads to a significant loss of market share and revenue as generic versions typically are priced lower. For patients, while generics offer cost savings, there can be concerns about bioequivalence and the quality of the API from different manufacturers [5]. Regulatory agencies scrutinize generic applications to ensure they meet the same standards of safety and efficacy as the originator product.
How does tofacitinib work in treating rheumatoid arthritis?
Tofacitinib is a Janus kinase (JAK) inhibitor. It works by blocking the activity of specific enzymes (JAKs) involved in signaling pathways that promote inflammation and immune responses. In conditions like rheumatoid arthritis, these pathways contribute to joint swelling, pain, and damage. By inhibiting JAKs, tofacitinib helps to reduce inflammation and slow disease progression [6].
What are the common side effects of tofacitinib?
Common side effects reported for tofacitinib include upper respiratory tract infections, headache, diarrhea, and increased levels of certain liver enzymes [7]. More serious risks can include serious infections, blood clots, heart attack, stroke, and certain types of cancer. Patients are advised to discuss potential side effects and their medical history with their healthcare provider before starting treatment [7].
Are there alternative treatments to tofacitinib for rheumatoid arthritis?
Yes, several alternative treatments are available for rheumatoid arthritis. These include other disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, and leflunomide. Biologic DMARDs, which target specific parts of the immune system, are also widely used, including tumor necrosis factor (TNF) inhibitors (e.g., adalimumab, etanercept), IL-6 inhibitors (e.g., tocilizumab), and B-cell depleting agents (e.g., rituximab) [8].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/tofacitinib/api-manufacturers
[2] https://www.drugpatentwatch.com/api-manufacturers
[3] https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/faqs
[6] https://www.drugpatentwatch.com/drug/tofacitinib/mechanism-of-action
[7] https://www.drugpatentwatch.com/drug/tofacitinib/side-effects
[8] https://www.drugpatentwatch.com/drug/tofacitinib/alternatives